Clinical Impact of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Associated <i>Clostridioides difficile</i> Infection Among Patients with Lung Cancer.

Onco Targets Ther · 2022 · PMC9805707 · PMID 36597497

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an unexpected trendno p-value reported

26 In the present study, conversely, we found an unexpected trend of an increased CDI risk in patients receiving first-generation EGFR-TKIs (gefitinib and erlotinib) compared with those receiving afatinib.

also in 275 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.